Current NDC auxiliary source row compounder:388

This page is keyed by dataset, FDA.report source record ID, and physical source row number. Empty values are shown rather than omitted.

Complete normalized row#

Record Source: ndc_compounder_zip
Product Ndc Raw: 72196-0431
Product Ndc: 72196-0431
Product Ndc Digits: 721960431
Product Type Name: HUMAN COMPOUNDED DRUG
Proprietary Name: Trophamine 3.5%/Dextrose 10% and Heparin 125 units 250ml bag
Proprietary Name Suffix: [empty]
Nonproprietary Name: Trophamine 3.5%/Dextrose 10% and Heparin 125 units 250ml bag
Dosage Form Name: SOLUTION
Route Name: INTRAVENOUS
Marketing Category Name: OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
Labeler Name: Central Admixture Pharmacy Services, Inc.
Establishment Name: Central Admixture Pharmacy Services, Inc.
Establishment Fei: [empty]
Substance Name: HEPARIN SODIUM; LYSINE ACETATE; SERINE; TYROSINE; N-ACETYLTYROSINE; THREONINE; CYSTEINE HYDROCHLORIDE; HISTIDINE; ARGININE; TAURINE; DEXTROSE MONOHYDRATE; LEUCINE; METHIONINE; GLUTAMIC ACID; PROLINE; ASPARTIC ACID; ISOLEUCINE; ALANINE; GLYCINE; PHENYLALANINE; TRYPTOPHAN; VALINE
Active Ingredients Info: 125 U/250 mL; 1.05 g/250 mL; .3325 g/250 mL; .0385 g/250 mL; .21 g/250 mL; .3675 g/250 mL; .021 g/250 mL; .42 g/250 mL; 1.05 g/250 mL; .021875 g/250 mL; 25 g/250 mL; 1.225 g/250 mL; .2975 g/250 mL; .4375 g/250 mL; .595 g/250 mL; .28 g/250 mL; .7175 g/250 mL; .4725 g/250 mL; .315 g/250 mL; .42 g/250 mL; .175 g/250 mL; .6825 g/250 mL
History Active Ingredients Raw: HEPARIN SODIUM; LYSINE ACETATE; SERINE; TYROSINE; N-ACETYLTYROSINE; THREONINE; CYSTEINE HYDROCHLORIDE; HISTIDINE; ARGININE; TAURINE; DEXTROSE MONOHYDRATE; LEUCINE; METHIONINE; GLUTAMIC ACID; PROLINE; ASPARTIC ACID; ISOLEUCINE; ALANINE; GLYCINE; PHENYLALANINE; TRYPTOPHAN; VALINE
History Active Ingredients Info Raw: 125 U/250 mL; 1.05 g/250 mL; .3325 g/250 mL; .0385 g/250 mL; .21 g/250 mL; .3675 g/250 mL; .021 g/250 mL; .42 g/250 mL; 1.05 g/250 mL; .021875 g/250 mL; 25 g/250 mL; 1.225 g/250 mL; .2975 g/250 mL; .4375 g/250 mL; .595 g/250 mL; .28 g/250 mL; .7175 g/250 mL; .4725 g/250 mL; .315 g/250 mL; .42 g/250 mL; .175 g/250 mL; .6825 g/250 mL
History Dosage Raw: SOLUTION
Dea Schedule: [empty]
Package Ndc Raw: 72196-0431-1
Package Ndc: 72196-0431-1
Package Ndc Digits: 7219604311
Package Ndc11: 72196043101
Package Description: 250 mL in 1 BAG (72196-0431-1)
Reporting Period Raw: 2024-2
Reporting Period: 2024-2
Normalization Status: valid
Source Url: https://www.accessdata.fda.gov/cder/compounders_ndc_directory.zip
Source Archive: compounders_ndc_directory.zip
Source File: compounders_ndc_directory.txt
Source Date: 2026-09-18
Source Last Modified: Fri, 18 Sep 2026 15:17:23 GMT
Source Archive Sha256: 222f6800f79cb1a0fa79431b7226bd6b34899999dbf086af51004a96774ada98
Source Member Sha256: f8d9743e5616579a34d614887e86a53913efa0a63d3138d59d2f87cbb4d0cc17
Source Record Id: compounder:388
Source Row Number: 388
Source Row Hash: 60be4c9f9b559333a01629ab1d99f98330f196986ae7b2117473a47a1330805f
Import Run Id: 20261018T022251Z
Loaded At: 2026-10-18 02:29:51

Exact raw FDA source fields#

{
    "ROUTENAME": "INTRAVENOUS",
    "PRODUCTNDC": "72196-0431",
    "DEASCHEDULE": "",
    "LABELERNAME": "Central Admixture Pharmacy Services, Inc.",
    "SUBSTANCENAME": "HEPARIN SODIUM; LYSINE ACETATE; SERINE; TYROSINE; N-ACETYLTYROSINE; THREONINE; CYSTEINE HYDROCHLORIDE; HISTIDINE; ARGININE; TAURINE; DEXTROSE MONOHYDRATE; LEUCINE; METHIONINE; GLUTAMIC ACID; PROLINE; ASPARTIC ACID; ISOLEUCINE; ALANINE; GLYCINE; PHENYLALANINE; TRYPTOPHAN; VALINE",
    "DOSAGEFORMNAME": "SOLUTION",
    "NDCPACKAGECODE": "72196-0431-1",
    "PRODUCTTYPENAME": "HUMAN COMPOUNDED DRUG",
    "PROPRIETARYNAME": "Trophamine 3.5%/Dextrose 10% and Heparin 125 units 250ml bag",
    "REPORTINGPERIOD": "2024-2",
    "NONPROPRIETARYNAME": "Trophamine 3.5%/Dextrose 10% and Heparin 125 units 250ml bag",
    "PACKAGEDESCRIPTION": "250 mL in 1 BAG (72196-0431-1) ",
    "ACTIVEINGREDIENTSINFO": "125 U/250 mL; 1.05 g/250 mL; .3325 g/250 mL; .0385 g/250 mL; .21 g/250 mL; .3675 g/250 mL; .021 g/250 mL; .42 g/250 mL; 1.05 g/250 mL; .021875 g/250 mL; 25 g/250 mL; 1.225 g/250 mL; .2975 g/250 mL; .4375 g/250 mL; .595 g/250 mL; .28 g/250 mL; .7175 g/250 mL; .4725 g/250 mL; .315 g/250 mL; .42 g/250 mL; .175 g/250 mL; .6825 g/250 mL",
    "MARKETINGCATEGORYNAME": "OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)",
    "PROPRIETARYNAMESUFFIX": ""
}

Normalization notes#

[]

Current status projection#

Dataset: compounder
Record Source: ndc_compounder_zip
Source Record Id: compounder:388
Source Row Number: 388
Status Scope: package
Lookup Ndc: 72196-0431-1
Lookup Ndc Digits: 7219604311
Product Ndc: 72196-0431
Product Ndc Digits: 721960431
Package Ndc: 72196-0431-1
Package Ndc Digits: 7219604311
Package Ndc11: 72196043101
Product Id: [empty]
Status Code: COMPOUNDER
Status Label: Outsourcing facility compounded drug report
Reporting Period Raw: 2024-2
Reporting Period: 2024-2
Source Table: fda_ndc_aux_compounder
Source File: compounders_ndc_directory.txt
Source Date: 2026-09-18
Source Row Hash: 60be4c9f9b559333a01629ab1d99f98330f196986ae7b2117473a47a1330805f
Import Run Id: 20261018T022251Z
Loaded At: 2026-10-18 02:29:51